Description

Ertugliflozin + Sitagliptin is a combination oral medication used to manage type 2 diabetes. It combines two different classes of drugs to improve blood sugar control. Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor.

Indication

This medication is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used for treating type 1 diabetes or for treating diabetic ketoacidosis.

Mechanism of Action

• Ertugliflozin (SGLT2 inhibitor): Ertugliflozin works by blocking the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing glucose from the urine back into the bloodstream. By inhibiting it, Ertugliflozin causes the kidneys to excrete more glucose in the urine, thereby lowering blood glucose levels.
• Sitagliptin (DPP-4 inhibitor): Sitagliptin works by inhibiting the enzyme DPP-4. This enzyme normally breaks down incretin hormones, such as GLP-1 and GIP, which are released after a meal. By blocking DPP-4, Sitagliptin increases the levels of these hormones, which in turn leads to increased insulin secretion and decreased glucagon secretion from the pancreas. The combined effect is a reduction in blood glucose levels.